Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium (Q37770780)

22 August 2017

1 reference

title

Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium (English)

1 reference

22 August 2017

1 reference

2

Margaret A Knowles

0 references

Peter J Goebell

series ordinal

1

object named as

Peter J Goebell

1 reference

22 August 2017

publication date

1 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

28

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

409-428

1 reference

Bladder cancer: clinical and pathological profile

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Urothelial tumorigenesis: a tale of divergent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Bladder cancer subtypes defined by genomic alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Structural and Functional Diversity in the FGf Receptor Multigene Family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

FrequentFGFR3mutations in urothelial papilloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Missense mutations to the TSC1 gene cause tuberous sclerosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Mutation of the 9q34 gene TSC1 in sporadic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Evidence for two candidate tumour suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumour cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Assessing TP53 status in human tumours to evaluate clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

The IARC TP53 database: new online mutation analysis and recommendations to users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Transcription regulation by mutant p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Mutant p53: an oncogenic transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

p53 alterations in human cancer: more questions than answers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Biological markers in superficial bladder tumors and their prognostic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

The immunocytochemical detection of p53 protein in cytological specimens: technical considerations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

p53 immunohistochemistry in bladder cancer. Combined analysis: a way to go?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

p53 immunohistochemistry in bladder cancer--a new approach to an old question

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

p53 in tumour pathology: can we trust immunohistochemistry?--Revisited!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

A population-based study of immunohistochemical detection of p53 alteration in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Amplification and overexpression of E2F3 in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

A variant in CDKAL1 influences insulin response and risk of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Loss of heterozygosity at chromosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Bladder cancer stage and outcome by array-based comparative genomic hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Somatic mutation of PTEN in bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Molecular analysis of PTEN and MXI1 in primary bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Pten haploinsufficiency accelerates formation of high-grade astrocytomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

HER-2 and TOP2A coamplification in urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Bladder cancer outcome and subtype classification by gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Incidental diagnosis of transitional cell carcinoma during percutaneous nephrolithotomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

The optimal management of T1G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Controversial issues and optimal management of stage T1G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Management of the first recurrence of T1G3 bladder cancer: does intravesical chemotherapy deserve a chance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

High-risk, high-grade (T1G3) bladder cancer: models versus reality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Organ preservation for T1G3 bladder cancer: is it feasible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Prognostic value of p53, Ki-67, microstaging and microvessel density in pT1G3 bladder tumors: creation of risk groups for progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Molecular evolution of multiple recurrent cancers of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Karyotypic characterization of urinary bladder transitional cell carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Rates of p16 (MTS1) mutations in primary tumors with 9p loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Deletion of the p16 and p15 Genes in Human Bladder Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Loss of P16 Expression and Chromosome 9p21 LOH in Predicting Outcome of Patients Affected by Superficial Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Alteration of the PATCHED locus in superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

PTCH gene mutations in invasive transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Definition of a 1-Mb homozygous deletion at 9q32-q33 in a human bladder-cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Initiation-development modelling of allelic losses on chromosome 9 in multifocal bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

The random development of LOH on chromosome 9q in superficial bladder cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Statistical behavior of complex cancer karyotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Natural history of urothelial inverted papilloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Inverted papilloma of the urinary bladder: a molecular genetic appraisal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Prediction models for transitional cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Prediction models in urology: are they any good, and how would we know anyway?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

Ten steps towards improving prognosis research.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.04.003

10.1016/J.UROLONC.2010.04.003

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference